ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / CRDF / news
NMRA (34) CSBR (20) CGTX (35) GRML (29) ⌘ Pro Terminal →

Why CRDF Stock dropped -5.09% Today — RQD Quant Desk Flash

$0.84 -5.09% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.83

Cardiff Oncology Inc. (CRDF) carries a Roarable Rating of E (Strong Sell) with 25/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $69.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CRDF Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CRDF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Cardiff Oncology Inc. (NASDAQ: CRDF) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 25/100 at a spot price of $0.84 (-5.09% 1D, market cap $69.2M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CRDF ranks #930 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CRDF compare to NMRA and CSBR in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CRDF carries a Roarable E (25/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NMRA (Neumora Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $69.0M) and CSBR (Champions Oncology Inc.) posts a E grade (20/100 RQD, P/E N/A, ROIC -26.9%, cap $66.9M). Among the 5-stock peer group, CRDF leads on earnings multiple (N/A) while CSBR leads on capital efficiency (-26.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CRDF?
▼

Per CRDF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001213037), Cardiff Oncology Inc. generated $593.0K in revenue (-13.2% YoY), -$45.9K in net income, and -$38.0M in free cash flow against $61.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.83 (-1.11%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (25/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510025
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk E
Cash (5)Whales (4)SEC (7)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-14.3% Base Target
$3 Bull$1 Base$1 Bear
📬 FREE CRDF RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CRDF)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (25/100 Composite)
🔍 WHY CRDF SCORES 25/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+7/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+6/20 pts (24% of score)

FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 38.9 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
33
Grade E$1.04-14.4% Next Q
Q2 (-2Q)
30
Grade E$0.89-10.1% Next Q
Q3 (-1Q)
28
Grade E$0.80+5% Next Q
Current
25
Grade E$0.84-10.7% Hist 90D α
Trajectory: E (33) → E (25)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CRDF Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CRDF currently carries a cautious 25/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.08) and Max Pain ($0.88) forces dealer call-delta covering toward $3.48.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CRDF• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CRDF Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 25%NO 75%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why CRDF Stock dropped -5.09% Today — RQD Quant Desk Flash

Cardiff Oncology Inc. (CRDF) dropped -5.09% to $0.84, trading at 3% of its 52-week range ($0.76 – $3.31). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 3% of its 52-week range ($0.76 – $3.31) with RSI-14 at 38.9 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.84 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live CRDF Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CRDF)

  • ✓Walkthrough of CRDF's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CRDF // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -49.09%🛡️ HOLDING TREND SUPPORT
2026-11-03O $0.91H $0.91L $0.84C $0.84VOL 126.9K
RES: $1.44SUP: $0.77SMA50: $1.08SMA200: $1.43
$2.31$1.89$1.47$1.05$0.63RES $1.44SUP $0.77$0.842026-05-042026-06-172026-08-042026-09-172026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CRDF Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CRDF Butterfly Map → + Track CRDF →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -13.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CRDF today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CRDF. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CRDF today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CRDF)

Health Care Rank #930 of 1015 ⚔️ NMRA vs CRDF Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CRDF vs. NMRA, CSBR, CGTX, GRML)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Cardiff Oncology Inc. (CRDF) ranks #930 by composite RQD confidence (25/100, grade E) and #697 by equity capitalization ($69.2M). Within this direct 5-issuer industry benchmark cohort, CRDF leads on earnings valuation at N/A trailing P/E, while CSBR leads on capital efficiency and profitability with -26.9% ROIC and 48.0% gross margin. CGTX currently holds the highest overall quantitative score in the immediate peer group at 35/100 (D-) compared with CRDF at 25/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CRDF ACTIVE
Cardiff Oncology Inc.
E 25/100 — — -35.0% -5.09% $69.2M Benchmark Subject
NMRA
Neumora Therapeutics Inc.
E 34/100 — — -35.0% +34.99% $69.0M /nmra-vs-crdf →
CSBR
Champions Oncology Inc.
E 20/100 — 48.0% -26.9% 0.00% $66.9M /csbr-vs-crdf →
CGTX
Cognition Therapeutics Inc.
D- 35/100 — — -35.0% +1.63% $66.4M /cgtx-vs-crdf →
GRML
Greenland Mines Ltd.
E 29/100 — — -35.0% -12.88% $62.7M /grml-vs-crdf →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001213037 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cardiff Oncology Inc. (CRDF) reported GAAP revenue of $593.0K (-13.2% vs. FY2024 revenue of $683.0K , and +21.5% cumulative change since FY2023) , GAAP net income of -$45.9K, operating cash flow of -$37.9M, and free cash flow of -$38.0M (-0.5% YoY). On the balance sheet, CRDF closed FY2025 with $61.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $593.0K -$45.9K -$37.9M -$38.0M $61.9M —
FY2024 (FY) 2024-12-31 $683.0K -$45.4K -$37.7M -$37.8M $97.2M —
FY2023 (FY) 2023-12-31 $488.0K -$41.4K -$30.9M -$30.9M — —

3. CRDF Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CRDF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Cardiff Oncology Inc. (NASDAQ: CRDF) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 25/100 at a spot price of $0.84 (-5.09% 1D, market cap $69.2M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CRDF ranks #930 in composite RQD confidence.

How does CRDF compare to NMRA and CSBR in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CRDF carries a Roarable E (25/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NMRA (Neumora Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $69.0M) and CSBR (Champions Oncology Inc.) posts a E grade (20/100 RQD, P/E N/A, ROIC -26.9%, cap $66.9M). Among the 5-stock peer group, CRDF leads on earnings multiple (N/A) while CSBR leads on capital efficiency (-26.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CRDF?

Per CRDF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001213037), Cardiff Oncology Inc. generated $593.0K in revenue (-13.2% YoY), -$45.9K in net income, and -$38.0M in free cash flow against $61.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CRDF trading relative to its 50-day, 200-day, and 52-week technical levels?

CRDF last traded at $0.84 (-5.09% on volume of 467,452 shares), positioning the stock -22.22% below its 50-day simple moving average ($1.08) and -41.26% below its 200-day simple moving average ($1.43). Across its 52-week range of $0.76 to $3.31, CRDF sits at the 3.1% percentile with a 14-day RSI of 38.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.94).

Direct Sub-Reports: CRDF RQD Cockpit CRDF 12M Forecast CRDF Earnings & Move CRDF Dividends & DRIP CRDF Insiders & 13F CRDF Whale Options CRDF Profit Sankey CRDF News & Why
ROARABLE RATING BRIEF • RQD 25/100 (E) ✓ SEC XBRL & RQD VERIFIED

CRDF — Cardiff Oncology Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Cardiff Oncology Inc. (CRDF) earns a live Roarable RQD composite score of 25/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.84 (-5.09% 1D, market capitalization $69.2M).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (4/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (7/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Cardiff Oncology Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. The company operates as a clinical-stage entity.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Cardiff Oncology Inc. (CRDF) reported $593.0K in annual revenue (up from $683.0K in FY2024, -13.2% YoY) and -$45.9K in GAAP net income. Over the multi-year SEC filing window from FY2023 ($488.0K revenue, -$41.4K net income) through FY2025, CRDF scaled operating cash flow to -$37.9M and free cash flow to -$38.0M, backed by $61.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 25/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 4/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $0.76 – $3.31 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The most relevant second-order consideration visible in the data is the approved increase in authorized shares to 300 million, which a prospective investor could track for dilution effects on per-share value given the $0.89 price and $70.9M market capitalization.

  • Key Question #1: Can CRDF sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $593.0K and free cash flow of -$38.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CRDF's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CRDF Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cardiff Oncology Inc. (CRDF) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CRDF Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CRDF Bull vs. Bear Conversation Board — What's Your Call at $0.84?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CRDF 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CRDF:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $1.14 (+28.1%)
📌 Pinned Debate

Institutional accumulation and options positioning earn the highest RQD pillar score (15/20), signaling some institutional interest des

Picked up a starter position in CRDF in my $100K Virtual Cash book at $0.89. Institutional accumulation and options positioning earn the highest RQD pillar score (15/20), signaling some institutional interest despite weak fundamentals.. Trading inside a $0.76–$3.31 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.

SectorRotator 🐂 BULL

@MultipleCompression Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Biological Products (No Diagnostic Substances). If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $0.72 (-19.1%)
Spot @ $0.89

With FY 2025 operating income of -$49.0M against revenue of $0.6M, a Piotroski F-Score of 1/9, and cash falling from $51.5M to $17.5M,

Careful chasing CRDF at $0.89. With FY 2025 operating income of -$49.0M against revenue of $0.6M, a Piotroski F-Score of 1/9, and cash falling from $51.5M to $17.5M, the balance sheet is under pressure.. Gross margin is 0.0%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $0.72 on multiple compression.

LIVE TAPE